Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
apharm.com under the link Company Risk Factors and detailed inour filings with the Securities and Exchange Commission. We assume noobligation to update any forward-looking statements as a result of newinformation or future events or developments. Our press releases may bereviewed at http://www.acurapharm.com .
Date:2/27/2008
apharm.com under the link, "Company Risk Factors" and detailed in
our filings with the Securities and Exchange Commission. We assume no
obligation to update any forward-looking statements as a result of new
information or future events or developments. Our press releases may be
reviewed at
http://www.acurapharm.com.
'/>"/>SOURCE Acura Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology2.
Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH3.
Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director4.
Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR5.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma6.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference7.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.8.
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study9.
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum10.
ACG Announces Major Gift by Salix Pharmaceuticals, Inc.11.
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors